Potential of hypoxic marker and OET for prediction of immunotherapy in advanced lung cancer

2022 Fiscal Year Final Research Report

• Project/Area Number: 20K08118
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Review Section: Basic Section 52040:Radiological sciences-related
• Research Institution: Saitama Medical University
• Principal Investigator: Kaira Kyoichi 埼玉医科大学, 医学部, 教授 (40400783)
• Project Period (FY): 2020-04-01 – 2023-03-31
• Keywords: 免疫治療 / 低酸素 / PET / 肺癌 / 免疫微小環境

Outline of Final Research Achievements

In vitro study using lung cancer cell lines demonstrated the decrease of FDG and FMISO uptake within tumor cells by the inhibition of HIF-1. There was significant relationship between FMISO uptake and HIF-1, but, the expression of PD-L1 was not significantly associated with the uptake of both PET tracer. PD-L1, CD4, CD8, FOXP3, HIF-1α were analyzed in 100 patients with lung cancer who received PD-1 inhibitor by immunohistochemistry. The high expression of HIF-1α was significantly related to the resistance of PD-1 inhibitor. As monitoring of immunotherapy, clinical trial using FMISO-PET was approved and on-going at our institution. Until now, 16 patients were registered for further analysis. However, the war of Ukraine and Russia was not stopped, thus, the drug of FMISO was not imported. The progress of our study is delay. The remaining patients are recruiting.

Free Research Field

臨床腫瘍学

Academic Significance and Societal Importance of the Research Achievements

本研究は癌治療で中心の免疫治療の治療効果を予測するための非侵襲的なPETでの有用性を検討する内容である。FDGは一般使用されているが、低酸素を評価するFMISO-PETは研究用のPETではあるが、免疫治療の効果を評価するのに優れている可能性が期待されている。この研究で低酸素マーカーと免疫治療の関連性は認められ、特にその発現が治療抵抗性に関係している。FMISO-PETの免疫治療のモニタリングの有用性が主目的であり、臨床試験を実施して20例中16例が登録された。これはロシアとウクライナ紛争のためFMISO試薬がしばらく届かず試験が順調にいかなかった。現在、試験進行中で終了後解析予定である。